Trials, publications and grants since Nov 2024.
Publication
Early Changes in Lymphocyte Counts Predict Clinical Outcomes in Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab.
Journal of gastroenterology and hepatology, Oct 2026
Publication
Prognostic Value of the FIB-3 Index in Patients With Hepatic Encephalopathy Receiving Rifaximin: A Multicenter Retrospective Analysis.
Hepatology research : the official journal of the Japan Society of Hepatology, Sept 2026
Publication
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.
Liver international : official journal of the International Association for the Study of the Liver, Aug 2026
Publication
Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.
Hepatology research : the official journal of the Japan Society of Hepatology, Jul 2026
Publication
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.
Journal of gastroenterology and hepatology, May 2026
Publication
Compensatory Hepatic Hypertrophy After Carbon Ion Radiotherapy for Hepatocellular Carcinoma: Factors Associated With Its Development and Relationship With Prognosis.
Hepatology research : the official journal of the Japan Society of Hepatology, May 2026
Publication
Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma.
Hepatology research : the official journal of the Japan Society of Hepatology, May 2026
Publication
Efficacy and Safety of Stereotactic Body Radiation Therapy in Patients With Hepatocellular Carcinoma in the Caudate Lobe: A Comparative Study With Radiofrequency Ablation.
Hepatology research : the official journal of the Japan Society of Hepatology, Apr 2026
Publication
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
Hepatology research : the official journal of the Japan Society of Hepatology, Apr 2026
Publication
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab.
Hepatology research : the official journal of the Japan Society of Hepatology, Apr 2026
Publication
Long-Term Outcomes of Sofosbuvir/Velpatasvir Treatment for Hepatitis C Virus-Related Decompensated Cirrhosis: A Retrospective Multicenter Cohort Study.
Hepatology research : the official journal of the Japan Society of Hepatology, Apr 2026
Publication
Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab.
Liver international : official journal of the International Association for the Study of the Liver, Apr 2026
Publication
The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy.
Hepatology research : the official journal of the Japan Society of Hepatology, Mar 2026
Publication
Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd-EOB-DTPA-MRI.
Hepatology research : the official journal of the Japan Society of Hepatology, Mar 2026
Publication
Efficacy of Lenvatinib as Second-Line Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Current oncology (Toronto, Ont.), Mar 2026
Publication
Particle Radiation Therapy With Immunotherapy for Advanced Hepatocellular Carcinoma: Emerging Evidence and Remaining Questions.
Liver international : official journal of the International Association for the Study of the Liver, Mar 2026
Publication
Clinical Utility of the Apolipoprotein A2 Isoform Index as a Tumor Marker for Pancreatic Cancer.
JGH open : an open access journal of gastroenterology and hepatology, Feb 2026
Publication
Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice.
Cancer medicine, Feb 2026
Publication
Effect of Butyrate-Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab.
JGH open : an open access journal of gastroenterology and hepatology, Jan 2026
Publication
Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World Study.
Hepatology research : the official journal of the Japan Society of Hepatology, Jan 2026
Publication
Clinical Utility of the aMAP Risk Score for Predicting the Recurrence of Hepatic Encephalopathy After Rifaximin Treatment in Patients With Liver Cirrhosis: A Retrospective Cohort Study.
Hepatology research : the official journal of the Japan Society of Hepatology, Jan 2026
Publication
Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B.
Liver international : official journal of the International Association for the Study of the Liver, Jan 2026
Publication
Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.
Journal of gastroenterology and hepatology, Nov 2025
Publication
Tocilizumab for steroid-refractory hemophagocytic syndrome after durvalumab and tremelimumab for advanced hepatocellular carcinoma.
Clinical journal of gastroenterology, Nov 2025
Publication
Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early-Stage Viral Disease.
Hepatology research : the official journal of the Japan Society of Hepatology, Nov 2025
Publication
Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus Bevacizumab.
Liver international : official journal of the International Association for the Study of the Liver, Oct 2025
Publication
Efficacy and Safety of the Combination of Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: A Real-World Retrospective Cohort Study.
Biomedicines, Aug 2025
Publication
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis.
Hepatology research : the official journal of the Japan Society of Hepatology, Aug 2025
Publication
Vascular Invasion Within the Resectability Criteria Is a Prognostic Factor in Patients Treated With Atezolizumab and Bevacizumab.
Liver international : official journal of the International Association for the Study of the Liver, Aug 2025
Publication
Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre Study.
Liver international : official journal of the International Association for the Study of the Liver, Jul 2025